EP Patent

EP2565202A1 — Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability

Assigned to Sanwa Kagaku Kenkyusho Co Ltd · Expires 2013-03-06 · 13y expired

What this patent protects

The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a pa…

USPTO Abstract

The present invention aims at providing a peptide fragment capable of improving biostability of a bioactive substance while maintaining the activity of the bioactive substance, and a bioactive substance to which the peptide fragment is added. The present invention relates to a partial peptide of a GA module having 5 to 25 amino acids, including a partial sequence of a GA module (SEQ ID NO: 1) and the amino acid sequence Ile-Asp-Glu-Ile-Leu (SEQ ID NO: 2), and a bioactive complex in which the partial peptide of the GA module is bound to a bioactive substance. The bioactive substance includes GLP-1, GLP-2, GIP, VIP, somatostatin, amylin, ghrelin, derivatives thereof, and the like.

Drugs covered by this patent

Patent Metadata

Patent number
EP2565202A1
Jurisdiction
EP
Classification
—
Expires
2013-03-06
Drug substance claim
No
Drug product claim
No
Assignee
Sanwa Kagaku Kenkyusho Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.